摘要
BACKGROUND： Encephalofluctuograph Technology （ET） is an advanced and non-traumatic analytical method of brain function. ET can acquire super-slow waves from electroencephalic signals. Studies have shown that these particular spectra can reflect neurochemical processes in the brain. OBJECTIVE： To verify neurotransmitter changes in the brains Parkinson＇s disease （PD） patients through the use of ET. DESIGN, TIME AND SETTING： A non-randomized concurrent control experiment was performed at the Department of Neurology in Southern Building, General Hospital of Chinese PLA from August to December 2007. PARTICIPANTS： Sixty-one outpatients with PD were selected from the General Hospital of Chinese PLA from August 2007 to December 2007. In addition, 48 healthy subjects were selected as normal controls. METHODS： All patients underwent assessment of the sub scale Ⅱ, Ⅲ and V of the Unified Parkinson＇s Disease Rating Scale （UPDRS）, in which part Ⅱ was used to inform activity of daily living, part Ⅲ reflected athletic ability, and part Ⅴ was the Hoehn ＆ Yahr grade for symptoms evaluation. Correlation analysis was performed between dopamine levels and UPDRS assessment. Neurotransmitter changes were observed forty-eight prior to and 1.5 hours after medicating with Benserazide. The S1, S2, S4, S5, S7, and S 11 spectras respectively reflect gamma-aminobutyric acid （GABA）, glutamic acid （Glu）, 5-hydroxytryptamine （5-HT）, acetylcholine （ACh）, norepinephrine, and dopamine. MAIN OUTCOME MEASURES： Neurotransmitter changes in the brains of all subjects, and correlations between dopamine concentrations and UPDRS assessment. Neurotransmitter changes in a subgroup of patients prior to and 1.5 hours after medicating with Benserazide. RESULTS： Concentrations of 5-HT, ACh, and norepinephrine were decreased in the PD group, and GABA was increased. However, there was no significant difference compared with the normal control group （P 〉 0.05）. The level of dopamine in PD group was significantly lower than that in the control group （P 〈 0.01 ）. Dopamine concentrations in PD patients negatively correlated with UPDRS scores and the Hoehn ＆Yahr grade range （r = 0.4601, -0.4301, P 〈 0.01）. Dopamine levels increased significantly in PD patients 1.5 hours after medicating with Benserazide compared with before （P 〈 0.01）. CONCLUSION： Detection by ET demonstrated that dopamine concentrations were significantly decreased in the brains of PD patients, as well as played a role in the course of pathogenesis and therapy. These results provided useful information for future non-traumatic of PD.
BACKGROUND： Encephalofluctuograph Technology （ET） is an advanced and non-traumatic analytical method of brain function. ET can acquire super-slow waves from electroencephalic signals. Studies have shown that these particular spectra can reflect neurochemical processes in the brain. OBJECTIVE： To verify neurotransmitter changes in the brains Parkinson＇s disease （PD） patients through the use of ET. DESIGN, TIME AND SETTING： A non-randomized concurrent control experiment was performed at the Department of Neurology in Southern Building, General Hospital of Chinese PLA from August to December 2007. PARTICIPANTS： Sixty-one outpatients with PD were selected from the General Hospital of Chinese PLA from August 2007 to December 2007. In addition, 48 healthy subjects were selected as normal controls. METHODS： All patients underwent assessment of the sub scale Ⅱ, Ⅲ and V of the Unified Parkinson＇s Disease Rating Scale （UPDRS）, in which part Ⅱ was used to inform activity of daily living, part Ⅲ reflected athletic ability, and part Ⅴ was the Hoehn ＆ Yahr grade for symptoms evaluation. Correlation analysis was performed between dopamine levels and UPDRS assessment. Neurotransmitter changes were observed forty-eight prior to and 1.5 hours after medicating with Benserazide. The S1, S2, S4, S5, S7, and S 11 spectras respectively reflect gamma-aminobutyric acid （GABA）, glutamic acid （Glu）, 5-hydroxytryptamine （5-HT）, acetylcholine （ACh）, norepinephrine, and dopamine. MAIN OUTCOME MEASURES： Neurotransmitter changes in the brains of all subjects, and correlations between dopamine concentrations and UPDRS assessment. Neurotransmitter changes in a subgroup of patients prior to and 1.5 hours after medicating with Benserazide. RESULTS： Concentrations of 5-HT, ACh, and norepinephrine were decreased in the PD group, and GABA was increased. However, there was no significant difference compared with the normal control group （P 〉 0.05）. The level of dopamine in PD group was significantly lower than that in the control group （P 〈 0.01 ）. Dopamine concentrations in PD patients negatively correlated with UPDRS scores and the Hoehn ＆Yahr grade range （r = 0.4601, -0.4301, P 〈 0.01）. Dopamine levels increased significantly in PD patients 1.5 hours after medicating with Benserazide compared with before （P 〈 0.01）. CONCLUSION： Detection by ET demonstrated that dopamine concentrations were significantly decreased in the brains of PD patients, as well as played a role in the course of pathogenesis and therapy. These results provided useful information for future non-traumatic of PD.
